Tech Company Financing Transactions
Allink Biotherapeutics Funding Round
Allink Biotherapeutics, based in Shanghai, received $47 million in investment from Legend Capital, Meituan and 5Y Capital.
Transaction Overview
Company Name
Announced On
12/16/2025
Transaction Type
Venture Equity
Amount
$47,000,000
Round
Series A
Investors
Legend Capital (Lead Investor)
Meituan (Lead Investor)
Proceeds Purpose
The company intends to use the funds to help advance global clinical development for its two leading programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2nd Floor, South Building, No. 2966, Jinke Road, Pudong New
Shanghai, Undisclosed
China
Shanghai, Undisclosed
China
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Shanghai Allink Biotherapeutics Co., Ltd. established in 2023, is a pioneering biotechnology company specializing in bispecific antibody and antibody-drug conjugates (ADCs). The company's experienced R&D focuses on the discovery and clinical development of a diverse of FIC/BIC therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Hui Feng
Chief Operating Officer
Kehua Emba
VP - R & D
Li Li
VP - R & D
Xiaolin Wang
Browse more venture capital transactions:
Prev: 12/16/2025: Agreenculture venture capital transaction
Next: 12/16/2025: Woodchuck venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs